Last reviewed · How we verify
Chemical-first
This drug targets the SGLT2 receptor to reduce glucose reabsorption in the kidneys.
This drug targets the SGLT2 receptor to reduce glucose reabsorption in the kidneys. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Chemical-first |
|---|---|
| Also known as | procainamide |
| Sponsor | University of British Columbia |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, the drug decreases glucose levels in the blood, which can help improve glycemic control in patients with diabetes. This mechanism of action is distinct from other diabetes treatments that primarily target insulin secretion or sensitivity.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
- Increased risk of increased urination
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Early Methylene Blue in the Microhemodynamics of Septic Patients (PHASE2, PHASE3)
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemical-first CI brief — competitive landscape report
- Chemical-first updates RSS · CI watch RSS
- University of British Columbia portfolio CI